Search

Coherus Oncology Inc

Fermé

SecteurSoins de santé

1.11 -0.89

Résumé

Variation du prix de l'action

24h

Actuel

Min

1.12

Max

1.1400000000000001

Chiffres clés

By Trading Economics

Revenu

-21M

-59M

Ventes

2M

14M

P/E

Moyenne du Secteur

3.509

55.725

BPA

-0.22

Marge bénéficiaire

-412.092

Employés

144

EBITDA

3.7M

-30M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+585.84% upside

Dividendes

By Acuity

Prochains Résultats

5 nov. 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-10M

212M

Ouverture précédente

2

Clôture précédente

1.11

Sentiment de l'Actualité

By Acuity

50%

50%

95 / 339 Classement par Healthcare

Coherus Oncology Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

25 sept. 2026, 20:07 UTC

Coherus Oncology Inc shares fell sharply, closing at their lowest point of the day, continuing a trend of lower performance over the past four sessions.

24 sept. 2026, 23:50 UTC

Coherus Oncology Inc saw a modest increase in after-market trading, rebounding from four consecutive sessions of declines.

23 sept. 2026, 19:51 UTC

News

Coherus Oncology Inc shares fell sharply as the company appointed Oppenheimer & Co. to advise on the sale of its Legacy BioSim Assets.

22 sept. 2026, 20:01 UTC

Coherus Oncology Inc shares fell sharply, reversing from an early high and currently trading significantly below Monday's close and its 20-day moving average.

21 sept. 2026, 20:01 UTC

Coherus Oncology Inc is trading higher, rebounding from an early low and peaking in the early afternoon, currently above its 20-day moving average.

18 sept. 2026, 20:02 UTC

Coherus Oncology Inc is advancing sharply, achieving its highest cumulative return of the day, despite remaining below its 20-day moving average.

17 sept. 2026, 20:01 UTC

Coherus Oncology Inc is rising, reaching a peak return today, although it remains below its 20-day moving average and near the lower end of its one-month range.

16 sept. 2026, 19:03 UTC

Coherus Oncology Inc shares fell sharply, continuing a notable decline since Tuesday's close and remaining well below their 20-day moving average.

15 sept. 2026, 20:01 UTC

Coherus Oncology Inc shares are trading lower amid negative market sentiment following a significant drop in the NY Empire State Manufacturing Index for September.

14 sept. 2026, 20:08 UTC

Coherus Oncology Inc shares are higher during Monday's session, continuing a significant advance since Friday's close amid broader market trends and inflation concerns.

9 sept. 2026, 20:07 UTC

Coherus Oncology Inc's shares are lower today, continuing a downward trend since Tuesday. The stock reached a session low amid broader market weakness.

2 sept. 2026, 19:46 UTC

Coherus Oncology Inc. shares are higher today, maintaining momentum since Tuesday's close and remaining above the 20-day moving average.

1 sept. 2026, 20:09 UTC

Coherus Oncology Inc is gaining as the Biotechnology sub-sector shows significant upward movement. The stock remains stable, finishing near its one-month range high.

31 août 2026, 20:02 UTC

News

Coherus Oncology shares are lower despite announcing participation in upcoming investor conferences and plans to enhance sales of its PD-1 inhibitor, LOQTORZI.

28 août 2026, 23:06 UTC

News

Coherus Oncology's $50 million common share offering pressures shares lower in after-market trading, marking a pullback from recent highs.

27 août 2026, 19:46 UTC

Coherus Oncology Inc shares are higher today, continuing an upward trend over three consecutive sessions. The stock remains above its 20-day moving average.

26 août 2026, 19:35 UTC

Coherus Oncology Inc is trading higher, maintaining upward momentum since Tuesday's close and performing well above its 20-day moving average.

25 août 2026, 20:07 UTC

Coherus Oncology Inc. shares are trading roughly flat amid easing Treasury yields, which typically support equities and enhance investor sentiment toward risk assets.

24 août 2026, 20:04 UTC

Coherus Oncology Inc shares are lower today, continuing a broader market decline. No specific company news has been identified to explain the movement.

21 août 2026, 20:01 UTC

Correlated Moves

Coherus BioSciences Inc. shares are higher today, reflecting positive momentum in the biotechnology sector and broader trends in related equities since Thursday's close.

20 août 2026, 23:16 UTC

Coherus BioSciences Inc shares are higher in after-market trading, reflecting modest gains despite broader market pressures and no specific company news identified.

19 août 2026, 20:02 UTC

Coherus BioSciences remains roughly flat during Wednesday's session, with no specific news identified. The broader market also showed little change.

18 août 2026, 23:26 UTC

Coherus BioSciences Inc is trading higher in after-market hours, despite broader market pressures from rising bond yields and elevated oil prices.

17 août 2026, 23:41 UTC

News

Coherus BioSciences announced a special dividend of contingent value rights, boosting shares in after-market trading following the company's strategic asset sale initiative.

14 août 2026, 19:31 UTC

Coherus BioSciences Inc shares are higher today, despite no specific news. Broader market sentiment includes concerns over disappointing U.S. retail sales data.

13 août 2026, 19:46 UTC

Social Media

Coherus BioSciences Inc shares are lower, extending a four-session decline. Despite social media optimism, the stock remains below its 20-day moving average.

12 août 2026, 23:01 UTC

Coherus BioSciences Inc shares are trading higher in after-market hours, despite recent declines and no specific news to explain the movement.

11 août 2026, 19:36 UTC

Coherus BioSciences Inc shares are lower amid broader market sentiment influenced by geopolitical tensions and upcoming U.S. inflation reports. No specific company news identified.

10 août 2026, 23:31 UTC

Coherus BioSciences Inc shares are higher in after-market trading, advancing from a low of 0.81% to a high of 3.25% since Monday's close.

8 août 2026, 00:01 UTC

Coherus BioSciences Inc shares rose in after-market hours, recovering from earlier volatility and settling higher since Friday's close despite no specific news identified.

Comparaison

Variation de prix

Coherus Oncology Inc prévision

Objectif de Prix

By TipRanks

585.84% hausse

Prévisions sur 12 Mois

Moyen 7.75 USD  585.84%

Haut 10 USD

Bas 4 USD

Basé sur 4 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

4 ratings

4

Achat

0

Maintien

0

Vente

Sentiment

By Acuity

95 / 339Classement par Soins de santé

Sentiment de l'Actualité

Neutral

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Coherus Oncology Inc

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27. It is also developing CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody selectively targeting CCR8, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, an antibody targeting human ILT4 designed to improve anti-PD-1 clinical benefit by transforming an unfavorable TME to a more favorable TME. In addition, the company's licensed immuno-oncology programs include NZV930, an antibody designed to inhibit cluster of differentiation 73; and GSK4381562, an antibody targeting CD112R for the treatment of solid tumors. Further, it offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis. It collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc., as well as Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.